Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PreDICT: Predicting Success of Dry Eye Interventions
NCT04125134Phase 4Terminated
- Sponsor
- Tufts Medical Center
- Start
- Oct 2019
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Optive Advanced in dry eye disease (DED) (2 arms), sponsored by Tufts Medical Center. Primary endpoint: Change in SANDE severity score at 4 weeks. Started Oct 2019; status: terminated.
02
Drugs
Optive Advanced
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04125134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04125134.